Key result
The frameshifting inhibitor MTDB reduced SARS-CoV-2 titer by 3 orders of magnitude in infected Vero E6 cells, with an IC50 of 48 μM.
Why the study?
Programmed ribosomal frameshifting is key to translating the SARS-CoV-2 RNA genome to synthesize viral proteins, but its structural basis was not defined.
Effect estimate: IC50 48 μM
The study reveals the cryo-EM structure of the mammalian ribosome paused at the SARS-CoV-2 frameshifting site and demonstrates that targeting this pseudoknot with MTDB inhibits viral replication.
May support frameshifting as antiviral target; leaves open clinical translation for COVID-19.
Programmed ribosomal frameshifting is the key event during translation of the SARS-CoV-2 RNA genome allowing synthesis of the viral RNA-dependent RNA polymerase and downstream viral proteins. Here we present the cryo-EM structure of the mammalian ribosome in the process of translating viral RNA paused in a conformation primed for frameshifting. We observe that the viral RNA adopts a pseudoknot structure lodged at the mRNA entry channel of the ribosome to generate tension in the mRNA that leads to frameshifting. The nascent viral polyprotein that is being synthesized by the ribosome paused at the frameshifting site forms distinct interactions with the ribosomal polypeptide exit tunnel. We use biochemical experiments to validate our structural observations and to reveal mechanistic and regulatory features that influence the frameshifting efficiency. Finally, a compound previously shown to reduce frameshifting is able to inhibit SARS-CoV-2 replication in infected cells, establishing coronavirus frameshifting as target for antiviral intervention.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2020) studied SARS-CoV-2. MTDB vs. Solvent control was evaluated on SARS-CoV-2 titer reduction (IC50) (IC50 48 μM). The frameshifting inhibitor MTDB reduced SARS-CoV-2 titer by 3 orders of magnitude in infected Vero E6 cells, with an IC50 of 48 μM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: